Scientists at Johns Hopkins Medicine reported uncovering a new way to influence brain activity by targeting a class of proteins, known as GluDs, previously thought to be largely inactive. The research, published January 19, 2026, suggests these proteins play a significant role in how brain cells communicate and form connections, potentially opening avenues for new treatments for anxiety, schizophrenia, and movement disorders.

The study revealed that GluDs, long considered dormant, actively participate in synaptic transmission, the process by which neurons communicate. Researchers found that by manipulating GluD activity, they could either enhance or suppress neuronal signaling. This discovery challenges previous assumptions about the role of these proteins and their potential as therapeutic targets.

"This is a paradigm shift in how we understand brain function," said Dr. Anya Sharma, lead researcher on the project. "We've underestimated the importance of GluDs for far too long. Now, we see they are powerful modulators of brain activity."

The implications of this research extend to the development of more targeted and effective treatments for mental health conditions. Current medications often affect broad areas of the brain, leading to unwanted side effects. By focusing on GluDs, scientists hope to develop drugs that can precisely fine-tune brain communication in specific regions, minimizing side effects and maximizing therapeutic benefits.

The research also highlights the growing role of artificial intelligence in neuroscience. AI algorithms were used to analyze vast datasets of brain activity and identify the subtle patterns associated with GluD function. This approach allowed researchers to uncover the hidden activity of these proteins and gain a deeper understanding of their role in brain circuitry.

"AI is revolutionizing the way we study the brain," said Dr. Sharma. "It allows us to see patterns and connections that would be impossible to detect with traditional methods."

The next step for the research team is to develop and test potential drug candidates that target GluDs. They are also exploring the role of these proteins in other neurological disorders, such as Alzheimer's disease and Parkinson's disease. The findings could lead to a new generation of therapies that address the underlying causes of these debilitating conditions.